Post Transplant Cmv Infection Therapeutics
1. Livtencity patent expiration
Treatment: Treating post-transplant cmv infection/disease refractory to ganciclovir, valganciclovir, cidofovir or foscarnet by administering 800 or 1200 mg maribavir 2x daily where patient is concomitantly expos...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12295940 | TAKEDA PHARMS USA | Viral inhibitors, the synthesis thereof, and intermediates thereto |
Oct, 2043
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12447170 | TAKEDA PHARMS USA | NA |
Nov, 2042
(16 years from now) | |
| US12447169 | TAKEDA PHARMS USA | NA |
Oct, 2031
(5 years from now) | |
| US12433907 | TAKEDA PHARMS USA | NA |
Nov, 2042
(16 years from now) | |
| US12213989 | TAKEDA PHARMS USA | Use of maribavir in treatment regimens |
Nov, 2042
(16 years from now) | |
| US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Dosage: TABLET
More Information on Dosage
LIVTENCITY family patents
